Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

837681

	registered interest
	date	06/02/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	General Practitioners: Labour Turnover
	house id	1
	legislature	25259 pref label House of Commons
	question text	What estimate his Department has made of the number of GPs who plan to leave general practice in the next five years; and if he will make a statement.
	tabling member constituency	Rochdale
	tabling member printed	Tony Lloyd
	uin	903795
	answer	answer is ministerial correction date of answer 06/02/2018 answer text <p>We know that one of the main reasons GPs leave general practice is retirement. That is why we have put in place comprehensive measures to ensure we meet our commitment of an extra 5,000 GPs in the NHS by 2020. GP Career Plus, the GP Retention Scheme and the National GP Induction and Refresher Scheme will all help get valuable experienced GPs back into our NHS. 3,157 GP training places were also filled in 2017 – the highest number ever.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 06/02/2018 15:44:28 answering member 4067 label Biography information for Steve Brine
	tabling member	450 label Biography information for Tony Lloyd

828794

	registered interest
	date	23/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Kidney Diseases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State, if he will take steps to ensure that people with diabetes are offered urine and blood tests to check for chronic kidney disease.
	tabling member constituency	Sunderland Central
	tabling member printed	Julie Elliott
	uin	124426
	answer	answer is ministerial correction date of answer 31/01/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) has published guidance on ‘Chronic kidney disease in adults’ which sets out best practice for clinicians on the diagnosis, treatment, care, and support of patients with chronic kidney disease (CKD). The guidance also includes recommendations for those at risk of developing CKD, including people with diabetes. NHS England expects commissioners to take account of NICE guidelines when delivering services.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 31/01/2018 12:34:13 answering member 4067 label Biography information for Steve Brine
	tabling member	4127 label Biography information for Julie Elliott

830542

	registered interest
	date	25/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Liothyronine
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether he plans to reduce the cost of liothyronine by procuring the drug from foreign suppliers; and if he will make a statement.
	tabling member constituency	Twickenham
	tabling member printed	Sir Vince Cable
	uin	125070
	answer	answer is ministerial correction date of answer 30/01/2018 answer text <p>The costs of branded medicines are controlled by the Pharmaceutical Price Regulation Scheme and the statutory scheme for branded medicines. Liothyronine is an unbranded generic medicine. For unbranded generic medicines, the Department encourages competition between suppliers to keep prices down. In primary care, community pharmacies are incentivised to source products at the lowest possible cost and in secondary care, competitive tenders ensure value-for-money to the National Health Service.</p><p> </p><p>Liothyronine is currently the subject of an investigation by the Competition and Markets Authority, which has provisionally found that the single supplier of the product abused its dominant position to overcharge the NHS by millions for liothyronine tablets. A provisional decision does not necessarily lead to an infringement decision. Where companies have breached competition law, the Department will seek damages and invest that money back into the NHS.</p><p> </p><p>Medicines legislation requires that only medicines licensed for use in the United Kingdom can be marketed in the UK.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 125067 question first answered 30/01/2018 17:14:17 answering member 4067 label Biography information for Steve Brine
	tabling member	207 label Biography information for Sir Vince Cable

830539

	registered interest
	date	25/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Liothyronine
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what estimate he has made of the money accrued to the public purse in relation to liothyronine under the (a) the voluntary Pharmaceutical Price Regulation Scheme and (b) the statutory scheme; and when those payments were made.
	tabling member constituency	Twickenham
	tabling member printed	Sir Vince Cable
	uin	125067
	answer	answer is ministerial correction date of answer 30/01/2018 answer text <p>The costs of branded medicines are controlled by the Pharmaceutical Price Regulation Scheme and the statutory scheme for branded medicines. Liothyronine is an unbranded generic medicine. For unbranded generic medicines, the Department encourages competition between suppliers to keep prices down. In primary care, community pharmacies are incentivised to source products at the lowest possible cost and in secondary care, competitive tenders ensure value-for-money to the National Health Service.</p><p> </p><p>Liothyronine is currently the subject of an investigation by the Competition and Markets Authority, which has provisionally found that the single supplier of the product abused its dominant position to overcharge the NHS by millions for liothyronine tablets. A provisional decision does not necessarily lead to an infringement decision. Where companies have breached competition law, the Department will seek damages and invest that money back into the NHS.</p><p> </p><p>Medicines legislation requires that only medicines licensed for use in the United Kingdom can be marketed in the UK.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 125070 question first answered 30/01/2018 17:14:17 answering member 4067 label Biography information for Steve Brine
	tabling member	207 label Biography information for Sir Vince Cable

830540

	registered interest
	date	25/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Liothyronine
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment he has made of the effect on the level of caseloads of consultant endocrinologists as a result of changes to the prescription of liothyronine.
	tabling member constituency	Twickenham
	tabling member printed	Sir Vince Cable
	uin	125068
	answer	answer is ministerial correction date of answer 30/01/2018 answer text <p>The Department has made no assessment. It is for local clinical commissioning groups in conjunction with local providers to make decisions on implementing NHS England’s guidance on liothyronine and, as part of their decision making, to determine the resources available to implement any change.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 30/01/2018 17:10:32 answering member 4067 label Biography information for Steve Brine
	tabling member	207 label Biography information for Sir Vince Cable

832894

	registered interest
	date	29/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Incinerators: Health Hazards
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, pursuant to the Answer of 31 October 2017 to Question 50386, on Incinerators: Health hazards, what information his Department holds on the planned publication date for the papers.
	tabling member constituency	Halton
	tabling member printed	Derek Twigg
	uin	125210
	answer	answer is ministerial correction date of answer 01/02/2018 answer text <p>It is expected that papers from the project on the health hazards of incinerators will be submitted by the Small Area Health Statistics Unit to peer reviewed journals in early 2018, and it is likely to be a few months after submission for the papers to be published.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 01/02/2018 11:38:58 answering member 4067 label Biography information for Steve Brine
	tabling member	429 label Biography information for Derek Twigg

819110

	registered interest
	date	09/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Energy Drinks: Children
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health what assessment he makes of the health effects of energy drink products on children aged 16 and under.
	tabling member constituency	West Lancashire
	tabling member printed	Rosie Cooper
	uin	121787
	answer	answer is ministerial correction date of answer 15/01/2018 answer text <p>Energy drinks can be high in caffeine and sugar. Based on the current evidence on the safety of caffeine, the Food Standard Agency advises that children, or other people sensitive to caffeine, should consume caffeine only in moderation.</p><p> </p><p>In its review of the evidence on “Carbohydrates and Health” (2015), the Scientific Advisory Committee on Nutrition (SACN) concluded that the consumption of sugar-sweetened beverages, as compared with non-calorically sweetened beverages, results in greater weight gain and increases in body mass index. Consuming too many sugary drinks can also cause tooth decay. In light of these findings, SACN recommended that the consumption of sugar-sweetened beverages (for example, sugary fizzy drinks, soft drinks and squash) should be minimised by both children and adults.</p><p> </p><p>Key measures in our world-leading childhood obesity plan, launched in August 2016, include the soft drinks industry levy and sugar reduction and wider reformulation programme, which will encourage the food and drink industry to reduce the amount of sugar in products popular with children, including energy drinks.</p><p> </p><p>The Government will continue to monitor the situation and any new emerging scientific evidence on the consumption of energy drinks.</p><p> </p><p>“Carbohydrates and Health” is available at:</p><p> </p><p><a href="http://www.gov.uk/government/publications/sacn-carbohydrates-and-health-report" target="_blank">www.gov.uk/government/publications/sacn-carbohydrates-and-health-report</a></p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 121788 question first answered 15/01/2018 11:56:59 answering member 4067 label Biography information for Steve Brine
	tabling member	1538 label Biography information for Rosie Cooper

820956

	registered interest
	date	11/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor: France
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health of Social Care, whether he has had recent discussions with his French counterpart on the cost-effectiveness of Orkambi in treating cystic fibrosis.
	tabling member constituency	Glasgow East
	tabling member printed	David Linden
	uin	122374
	answer	answer is ministerial correction date of answer 19/01/2018 answer text <p>We have had no such discussions. The National Institute for Health and Care Excellence (NICE) assessed the cost benefit of Orkambi and was unable to recommend it. Vertex has been encouraged to engage in negotiations with NHS England and if it comes forward with a new proposal, NICE will be able to reconsider.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 122362 122370 122372 question first answered 19/01/2018 11:36:20 answering member 4067 label Biography information for Steve Brine
	tabling member	4640 label Biography information for David Linden

823523

	registered interest
	date	16/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the extension of Orkambi's licence to treat patients aged six and over, what support his Department is giving to further negotiations among NICE, NHS England and the drug manufacturer, Vertex, on access to that medicine for people with cystic fibrosis.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	122992
	answer	answer is ministerial correction date of answer 24/01/2018 answer text <p>The Department wants patients with cystic fibrosis to benefit from clinically and cost effective treatments, and we welcome the on-going dialogue between Vertex and NHS England to pursue a deal that would make Orkambi available to National Health Service patients.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 24/01/2018 12:13:27 answering member 4067 label Biography information for Steve Brine
	tabling member	104 label Biography information for Crispin Blunt

833048

	registered interest
	date	29/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Orphan Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Office of Health Economics Report, Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries, published in March 2017, what steps he is taking to develop the Highly Specialised Technology appraisal process at NICE.
	tabling member constituency	Cambridge
	tabling member printed	Daniel Zeichner
	uin	125364
	answer	answer is ministerial correction date of answer 06/02/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes it uses in the development of its guidance and recommendations, including through its Highly Specialised Technologies (HST) programme. NICE periodically reviews its methods and processes to ensure that they remain fit for purpose for the National Health Service in England and introduced changes to its methods for the evaluation of technologies through its HST programme in April 2017 following a public consultation.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 06/02/2018 16:18:10 answering member 4067 label Biography information for Steve Brine
	tabling member	4382 label Biography information for Daniel Zeichner